We Believe the Only Acceptable Number for Sepsis Misdiagnosis is Zero

Every false-positive blood culture could result in patient harm.

{ addScript() })">

Steripath® enables sustained, near-zero blood culture contamination rates.1

Learn More

Company
News

News Magnolia Medical Technologies Files for Permanent Injunction Against Infringing Kurin Lock Products News Magnolia Medical’s Steripath® Initial Specimen Diversion Device® Only Device Clinically Proven to Meet CDC’s New Guidelines to Reduce Blood Culture Contamination News Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc. All News

The Cost of Blood Culture Contamination

Blood culture contamination and false-positive results for sepsis routinely lead to unnecessary and prolonged use of broad-spectrum antibiotics, which can have harmful clinical and cost consequences. 2

Patient Harm

3 million antibiotic-resistant and Clostridioides difficile Infection (CDI) each year and 48,000 people die.

1 in 5 patient experience adverse drug event (ADE) associated with antibiotic administration in acute care hospital setting.

Wasted Resources

$6 billion is spent by our U.S. healthcare system each year on unnecessary treatment associated with false-positive blood culture results. 49

This does not include the impact blood culture contamination can have on CMS key quality outcome metrics and hospital reimbursement.

Learn More

{ addScript() })">

Developed by Physicians. Backed by Science. Proven Results.

The Steripath® Initial Diversion Device® is the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination 3 for sepsis testing accuracy. Created by physicians, pathologists, clinical microbiologists and laboratorians, Steripath is the simple, all-in-one, evidence-backed solution that gives you the proven results you need for diagnostic stewardship to provide your patients with the best quality care.